Karyopharm Therapeutics Inc. KPTI Income Statement

Karyopharm therapeutics inc. (KPTI)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Sep'12
Revenues:
Total revenues
58,876	40,893	23,003	10,093	20,491	30,336	31,664	31,425	11,537	1,605	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Contract and grant revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	229	234	213	325	387	400	0	0	0
Operating expenses:
Cost of sales
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of sales
-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development
118,363	122,340	129,651	139,808	158,025	161,372	157,315	146,125	124,511	107,273	93,111	87,767	89,226	86,938	90,331	96,361	98,788	97,744	93,718	83,746	69,899	60,127	49,778	41,565	34,466	28,452	21,760	0	0	0
Selling, general and administrative
0	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
-	-	-	83,502	-	-	-	29,081	26,227	-	25,258	25,337	24,658	23,948	22,671	21,536	21,737	21,582	22,238	21,290	18,443	15,948	12,508	10,277	7,910	5,885	4,077	0	0	0
Total operating expenses
230,585	230,168	226,467	223,310	226,354	210,219	193,544	175,206	150,738	132,143	118,369	113,104	113,884	110,886	113,002	117,897	120,525	119,326	115,956	105,036	88,342	76,075	62,286	51,842	42,376	34,337	25,837	0	0	0
Loss from operations
-171,709	-189,275	-203,464	-213,217	-205,863	-179,883	-161,880	-143,781	-139,201	-130,538	-118,251	-112,938	-113,662	-110,732	-112,870	-117,738	-120,275	-119,076	-115,715	-104,849	-88,284	-75,846	-62,052	-51,629	-42,051	-33,950	-25,437	0	0	0
Other income (expense):
Interest income
4,626	5,422	6,088	6,049	5,290	4,028	2,692	2,048	1,807	1,698	1,624	1,481	1,398	1,284	1,176	1,104	1,042	897	689	470	220	97	0	0	0	-	-	-	-	-
Interest expense
19,158	15,647	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income (expense), net
-23	-50	-49	-72	-21	-33	-31	-44	-80	-81	-59	-27	-9	10	6	-2	60	-2	0	0	0	-	-	0	0	-	-	-	-	-
Total other expense, net
-14,555	-10,275	-5,634	-2,603	-222	1,502	2,661	2,004	1,727	1,617	1,565	1,454	1,389	1,294	1,182	1,102	1,102	895	658	0	0	-	0	-	-	-	-	0	-	-
Loss before income taxes
-186,264	-199,550	-209,098	-215,820	-206,085	-178,381	-159,219	-141,777	-137,474	-128,921	-116,686	-111,484	-112,273	-109,438	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Income tax provision
96	40	55	49	24	26	18	17	52	63	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-186,360	-199,590	-209,153	-215,869	-206,109	-178,407	-159,237	-141,794	-137,526	-128,984	-116,879	-111,664	-112,435	-109,577	-111,688	-116,636	-119,173	-118,181	-115,063	-104,414	-88,150	-75,777	-61,995	-51,592	-42,030	-33,947	-25,436	0	0	0
Net loss per share—basic and diluted
-0.78	-0.75	-0.67	-0.71	-1.09	-0.97	-0.79	-0.60	-0.78	-0.81	-0.65	-0.64	-0.71	-0.64	-0.69	-0.84	-0.75	-0.81	-0.85	-0.92	-0.74	-0.81	-0.61	-0.55	-0.46	3.45	-3.66	-2.86	-2.52	1,846,859.00
Weighted-average number of common shares outstanding used in net loss per share—basic and diluted
67	124,738	62,092	60,929	60	60,920	60,586	56,089	49,602	48,731	47,141	45,831	41,894	41,437	36,819	35,956	35,878	35,755	35,708	35,697	35,317	32,717	32,558	29,659	29,606	17,096	2,544	2,404	2,225	-0
Comprehensive loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-
Product revenue
Total revenues
0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
License and other revenue
Total revenues
0	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-